19:30 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample and mouse studies suggest promoting the expression of KIF16B, SELENOW and TESK2 could help prevent brain metastasis in lung cancer. In patients, low expression of KIF16B, SELENOW and TESK2 in primary...
20:15 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Sunovion's PD therapy NDA gets PDUFA date

Sunovion Pharmaceuticals Inc. said FDA accepted an NDA for apomorphine sublingual film (APL-130277) to treat "off" episodes in Parkinson's disease (PD). The PDUFA date is Jan. 29, 2019. Sunovion, a unit of Sumitomo Dainippon Pharma Co....
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
19:53 , Jul 28, 2017 |  BC Week In Review  |  Company News

Mitsubishi acquiring NeuroDerm

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) will acquire neurology company NeuroDerm Ltd. (NASDAQ:NDRM) for $1.1 billion at a price of $39 per share. The price is 17% premium over the share’s July 21 close of $33.20. The...
19:40 , Jul 24, 2017 |  BC Extra  |  Company News

Mitsubishi Tanabe acquiring NeuroDerm

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) is acquiring neurology company NeuroDerm Ltd. (NASDAQ:NDRM) for $39 per share, or about $1.1 billion. The price is a 17% premium on NeuroDerm's July 21 close of $33.20. The deal gives...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Cynapsus, Sumitomo Dainippon deal

Sumitomo’s Sunovion Pharmaceuticals Inc. unit will acquire Cynapsus for $40.50 per share in a cash deal the companies say values Cynapsus at about $624 million. The price is a 121% premium to Cynapsus’ close of...
07:00 , Aug 31, 2016 |  BC Extra  |  Top Story

Sunovion to acquire Cynapsus for $624M

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) announced after market close Wednesday that it will acquire neurology company Cynapsus Therapeutics Inc. (TSX:CTH; NASDAQ:CYNA) for about $624 million in cash. Sunovion...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

ND0701: Clinical trial started

NeuroDerm began a crossover bioequivalence trial to compare subcutaneous ND0701 apomorphine base vs. marketed subcutaneous apomorphine HCl for 12 hours in about 18 healthy volunteers. NeuroDerm Ltd. (NASDAQ:NDRM), Ness Ziona, Israel   Product: ND0701   Business:...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

APL-130277: Preliminary Phase III data

Preliminary data from 92 evaluable PD patients in the open-label, dose-escalation portion of the U.S. Phase III CTH-300 trial showed that sublingual APL-130227 improved mean MDS-UPDRS Part III score from baseline to 30 and 90...
07:00 , Jul 19, 2016 |  BC Extra  |  Clinical News

Cynapsus reports early Phase III data for PD candidate

Cynapsus Therapeutics Inc. (TSX:CTH; NASDAQ:CYNA) reported data from the open-label, dose-escalation portion of the Phase III CTH-300 study evaluating APL-130277 to treat "off" episodes in patients with Parkinson's disease (PD). In 92 evaluable PD patients,...